Tuesday, December 27, 2016 12:01:58 PM
Novo's rather abrupt departure from the oral insulin scene has left Oramed Pharmaceuticals Inc. (ORMP) shareholders caught between confused excitement and mild panic. This is also understandable. On the one hand, Novo's exit gives Oramed easier access to diabetes markets if its own oral insulin candidate ORMD-0801 succeeds. On the other hand, if Novo decided to ax its oral insulin program without even attempting a Phase IIb, doesn't that hint to the entire venture of oral insulin being doomed?
Oramed shares dove over 10% on the news but have been holding in a steady range since then. There are two questions that need to be answered to determine where Oramed goes from here. The first is, why did Novo shutter NN1953? The second is, can Oramed's own ORMD-0801 oral insulin succeed in its own right?
If Novo abandoned NN1953 because it thought the program was a failure, then the implication for Oramed's oral insulin program would be quite negative. If, however, there is an ulterior motive here, then Novo may have just abandoned a multibillion-dollar market to Oramed, assuming ORMD-0801 succeeds and gets approved. But why would Novo do that?
Recent ORMP News
- Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation • GlobeNewswire Inc. • 03/19/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:42:26 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 02/20/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:43:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:41:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:37:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:36:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:34:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:33:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:32:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 06:13:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 02:26:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:45:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:34:25 PM
- Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company • PR Newswire (US) • 09/22/2023 03:38:00 PM
- Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company • PR Newswire (US) • 09/21/2023 10:11:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM